查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2093168

真菌性角膜炎治療市場－2026-2032年全球市場預測

Fungal Keratitis Treatment Market - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 190 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，真菌性角膜炎治療市場規模將達到 1,47,185 億美元，年複合成長率為 6.58%。

主要市場統計數據
基準年 2025 9.417億美元
預計年份：2026年 9.9823億美元
預測年份 2032 1,471,850,000 美元
複合年成長率 (%) 6.58%

真菌性角膜炎治療市場概覽

真菌性角膜炎是一種威脅視力的角膜感染疾病，最常見的病原體是絲狀真菌，例如鐮刀菌屬和曲霉菌屬，以及酵母菌，例如念珠菌屬。此病與植物性眼外傷、配戴隱形眼鏡、接觸農業工人、眼表疾病、使用皮質類固醇、未能及時就診於眼科專科醫生密切相關。由於真菌會侵入角膜組織，因此診斷可能耗時較長，治療也極具挑戰性，需要長期眼藥水治療和密切後續觀察，嚴重病例還需進行手術介入。

真菌性角膜炎治療的突破性變革

隨著臨床實踐從常常延誤的經驗性治療轉向以病原體為導向的實證治療，真菌性角膜炎的治療模式正在發生顯著變化。以往僅依賴臨床觀察的治療方法，現在更廣泛地納入了角膜刮除術、顯微鏡檢查、培養、共聚焦顯微鏡、基於聚合酵素鏈鎖反應(PCR) 的診斷，以及在條件允許的情況下，影像輔助評估。這種轉變尤其重要，因為真菌性角膜炎的症狀可能與細菌性或皰疹性角膜炎相似。此外，早期不恰當地使用類固醇或延遲啟動抗真菌治療都可能使預後惡化。

人工智慧的累積影響

人工智慧 (AI) 正開始影響真菌性角膜炎的治療，它能夠改善臨床醫生檢測、分診、記錄和後續觀察角膜潰瘍的方式。 AI 驅動的影像分析可以幫助區分裂隙燈 X 光、前節光學同調斷層掃描(OCT) 和活體共聚焦顯微鏡影像中的感染性角膜炎模式。雖然臨床評估和專科醫生的微生物學確診仍然至關重要，但決策支援工具可以幫助識別高風險特徵，例如羽毛狀浸潤、衛星病灶、內皮斑塊、低血壓、潰瘍擴大和基質變薄。

按地區分類的主要發現

在亞太地區，由於氣候溫暖潮濕、農業活動活躍、植物性眼外傷發生率高以及農村地區角膜專科醫生資源匱乏，真菌性角膜炎的臨床負擔極重。在南亞和東南亞國家，絲狀真菌被認為是感染性角膜炎的主要病原體，而及時獲得那他黴素、顯微鏡檢查、培養設施和轉診網路對於提高醫療品質至關重要。在北美，治療情況則有所不同，隱形眼鏡相關性角膜炎、眼表疾病、術後風險和免疫抑制等因素都會導致病例發生。先進的診斷基礎設施、角膜專科醫療服務和藥房的普及為更個人化的治療提供了支持。

關鍵的群體特定見解

在東南亞國協，由於熱帶氣候、農業活動以及農村地區眼科醫療資源匱乏，真菌性角膜炎的治療至關重要，凸顯了分散式診斷、提高社區意識以及提供必要的抗真菌眼藥水的重要性。在海灣合作理事會（GCC）國家，先進的三級醫療基礎設施、國際患者流動、乾燥的環境條件影響眼表健康、外傷風險以及對微生物學和藥學能力支持的專業角膜保健服務的需求，共同決定了對真菌性角膜炎治療的需求。在歐盟，對藥品監管准入、跨境臨床標準、檢查室診斷、藥物安全監測以及合理使用抗菌藥物的重視，支持了真菌性角膜炎的系統性管理，即使罕見或複雜病例需要轉診至專科醫生。

主要國家的概況

在美國和加拿大，完善的角膜專科網路、診斷檢查室和先進的影像技術已相當成熟，治療通常圍繞著快速轉診、基於培養的治療、必要時使用複方抗真菌藥物以及對重症患者進行手術治療展開。相較之下，墨西哥和巴西的醫療保健資源分配差異很大。農業工人的感染風險、許多地區的熱帶氣候以及專科醫療服務的不穩定性，都影響著早期發現和更完善的轉診系統的建立。在英國、德國、法國、義大利和西班牙，成熟的眼科服務、診斷檢測和角膜移植計畫為真菌性角膜炎的治療提供了支持。然而，由於真菌性角膜炎不如細菌性角膜炎常見，且早期容易誤診，因此臨床診療仍然至關重要。

為行業領導者提供的實用建議

產業領導者應優先確保抗真菌藥物的可及性，加快診斷速度，並將其整合到臨床醫生的工作流程中。尤其是在治療延誤會導致可預防性角膜失明的地區，可靠供應眼用那他黴素、Amphotericin B製劑及相關唑類製劑至關重要。相關人員應支持檢驗的診斷流程，該流程應結合臨床評估、顯微鏡檢查、培養、必要的分子檢測以及用於監測治療進展的數位成像技術。

調查方法

本執行摘要基於系統性的二手研究途徑，參考了同行評審的眼科文獻、臨床實踐指南、公共衛生出版物、監管文件、疾病監測數據以及角膜感染疾病研究的證據。分析重點關注檢驗的臨床事實，包括真菌性角膜炎的病因、危險因子、診斷方法、治療方案、診療路徑、區域醫療資源取得差異以及新興技術的應用。

結論

真菌性角膜炎的治療仍然是角膜感染疾病診療的重中之重，因為診斷和治療的延遲可能導致瘢痕形成、穿孔、角膜移植，甚至不可逆的視力喪失。臨床實踐正朝著早期病原體鑑定、標準化抗真菌治療方案、改善轉診途徑以及更廣泛地應用影像學和數位化決策支援的方向發展。人工智慧、遠距眼科和先進的診斷技術可以加強分診和監測，尤其是在角膜專科醫生短缺的地區，但這些技術的應用必須經過嚴格的檢驗，並由臨床醫生進行監督。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 市場進入策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章：真菌性角膜炎治療市場：依真菌種類分類

  • 絲狀真菌
    • 鐮刀菌屬
    • 麴菌屬
    • 彎孢屬
  • 酵母樣真菌
    • 隱球菌屬
    • 念珠菌屬

第8章 真菌性角膜炎治療市場：依治療方式分類

  • 手術介入
  • 全身性抗真菌藥物
  • 局部抗真菌藥物

第9章：真菌性角膜炎治療藥物市場：依藥物類別分類

  • 唑類
    • 咪唑衍生物
      • Econazole
      • Ketoconazole
    • 三唑
      • Fluconazole
      • Itraconazole
      • Voriconazole
  • 棘白菌素類
    • 卡斯波方金
    • Micafungin
  • Polyenes
    • Amphotericin B
    • 那他黴素

第10章：真菌性角膜炎治療藥物市場：依給藥途徑分類

  • 外用
  • 角膜基質
  • 在前房

第11章：真菌性角膜炎治療市場：依年齡層別分類

  • 兒童
  • 成人
  • 老年人

第12章：真菌性角膜炎治療市場：依最終用戶分類

  • 門診手術中心
  • 診所
  • 眼科專科中心
  • 醫院

第13章：真菌性角膜炎治療市場：依分銷管道分類

  • 線下零售
  • 線上零售

第14章 真菌性角膜炎治療市場：按地區分類

  • 亞太地區
  • 北美洲
  • 拉丁美洲
  • 歐洲
  • 中東
  • 非洲

第15章：真菌性角膜炎治療市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第16章：真菌性角膜炎治療市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第17章 競爭格局

  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第18章：公司簡介

  • AbbVie Inc.
  • Alvogen Inc.
  • AS Lifesciences
  • Astellas Pharma Inc.
  • Aurolab
  • Bausch Health Companies Inc.
  • Cipla Ltd.
  • F2G Ltd.
  • Gilead Sciences Inc.
  • Glenmark Pharmaceuticals Ltd.
  • Grevis Pharmaceuticals Pvt. Ltd.
  • Iskon Remedies
  • Leadiant Biosciences Inc.
  • Lexicare Pharma Pvt. Ltd.
  • Merck KGaA
  • Novartis AG
  • Pfizer Inc.
  • Salvus Pharma
  • Santen Pharmaceutical Co., Ltd.
  • Scynexis Inc.
  • Sun Pharmaceutical Industries Ltd.
  • Taj Pharmaceuticals Ltd.
  • Viatris Inc.
  • Wellona Pharma
Product Code: MRR-FD3F12D54247

The Fungal Keratitis Treatment Market is projected to grow by USD 1,471.85 million at a CAGR of 6.58% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 941.70 million
Estimated Year [2026] USD 998.23 million
Forecast Year [2032] USD 1,471.85 million
CAGR (%) 6.58%

Fungal Keratitis Treatment Overview

Fungal keratitis is a sight-threatening corneal infection most commonly associated with filamentous fungi such as Fusarium and Aspergillus, as well as yeasts including Candida. The condition is strongly linked to ocular trauma involving vegetative matter, contact lens use, agricultural exposure, ocular surface disease, corticosteroid exposure, and delayed access to specialist eye care. Treatment remains clinically complex because fungal organisms penetrate corneal tissue, diagnostic confirmation can be slow, and therapeutic response often requires prolonged topical therapy, close monitoring, and, in severe cases, surgical intervention.

The fungal keratitis treatment landscape is shaped by the need for earlier diagnosis, better antifungal penetration, improved patient adherence, and stronger antimicrobial stewardship. Natamycin remains a key first-line topical option for many filamentous fungal infections, while amphotericin B and azole-based therapies are used depending on organism type, severity, availability, and clinician judgment. Adjunctive approaches, including therapeutic keratoplasty, corneal debridement, and emerging drug delivery strategies, are increasingly important when ulcers progress despite medical therapy. Across healthcare systems, demand is rising for integrated corneal infection pathways that combine microbiology, ophthalmology, pharmacy, digital imaging, and follow-up care to reduce corneal scarring, perforation, and preventable vision loss.

Transformative Shifts in Fungal Keratitis Care

The fungal keratitis treatment environment is undergoing meaningful change as clinical practice moves from delayed, empiric care toward organism-directed, evidence-informed management. Traditional dependence on clinical appearance alone is giving way to broader use of corneal scraping, microscopy, culture, confocal microscopy, polymerase chain reaction-based diagnostics, and image-supported assessment where available. This shift is particularly important because fungal keratitis can mimic bacterial or herpetic keratitis, and inappropriate early steroid use or delayed antifungal therapy can worsen outcomes.

Treatment strategies are also evolving from single-modality drug administration toward comprehensive corneal infection management. Clinicians are placing greater emphasis on early epithelial debridement to improve drug penetration, frequent loading-dose regimens during the acute phase, toxicity monitoring, and rapid escalation for nonresponding ulcers. Surgical decision-making is becoming more structured, with therapeutic keratoplasty considered for impending perforation, deep stromal invasion, uncontrolled infection, or extensive tissue loss. At the same time, health systems are prioritizing access to essential ophthalmic antifungals, standardized referral pathways, and community-level education for agricultural workers and contact lens users. These transformative shifts are strengthening the alignment between diagnosis, treatment selection, adherence support, and visual rehabilitation.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is beginning to influence fungal keratitis treatment by improving how clinicians detect, triage, document, and monitor corneal ulcers. AI-enabled image analysis can support differentiation of infectious keratitis patterns from slit-lamp photographs, anterior segment optical coherence tomography, and in vivo confocal microscopy images. While expert clinical evaluation and microbiological confirmation remain essential, decision-support tools can help flag high-risk features such as feathery infiltrates, satellite lesions, endothelial plaques, hypopyon, ulcer expansion, and stromal thinning.

The cumulative impact of artificial intelligence is expected to be most valuable in settings where specialist corneal care is limited. Teleophthalmology platforms combined with algorithmic risk stratification can help prioritize urgent referrals, monitor treatment response through serial imaging, and reduce delays between symptom onset and antifungal initiation. AI can also strengthen clinical research by standardizing lesion measurement, grading infiltrate density, tracking epithelial healing, and correlating imaging features with microbiology and outcomes. However, safe implementation requires validated datasets that reflect geographic diversity, fungal species variation, skin tone and ocular surface differences, and real-world imaging quality. For industry leaders, AI should be viewed as an adjunct to laboratory-supported care rather than a replacement for microbiology, ophthalmic examination, and clinician-led treatment decisions.

Key Regional Insights

Asia-Pacific carries a substantial clinical burden of fungal keratitis due to warm, humid climates, high agricultural activity, frequent ocular trauma with plant material, and variable access to corneal specialists in rural areas. Countries across South and Southeast Asia report filamentous fungi as major causes of infectious keratitis, making timely access to natamycin, microscopy, culture facilities, and referral networks central to care quality. North America presents a different treatment profile, with contact lens-associated keratitis, ocular surface disease, post-surgical risk, and immunosuppression contributing to cases; advanced diagnostic infrastructure, corneal subspecialty services, and access to compounding pharmacies support more individualized therapy.

Latin America reflects mixed epidemiology, with tropical and subtropical environments, agricultural exposure, and uneven specialist access shaping treatment needs. Europe benefits from structured ophthalmology networks, antimicrobial stewardship practices, and laboratory capacity, although cases related to contact lenses, trauma, and systemic risk factors continue to require rapid differentiation from bacterial keratitis. The Middle East shows demand for strengthened corneal infection pathways amid climate-related ocular surface stress, trauma exposure, and tertiary eye care concentration in urban centers. Africa faces some of the most significant access challenges, including delayed presentation, limited microbiology resources, low availability of ophthalmic antifungals in some settings, and higher risk of advanced ulcers requiring surgical management. Across all regions, the strongest treatment outcomes are associated with early recognition, organism confirmation, antifungal availability, adherence to intensive dosing, and timely surgical escalation when medically indicated.

Key Group Insights

ASEAN countries demonstrate high relevance for fungal keratitis treatment because tropical climates, agricultural work, and variable rural eye care access increase the importance of decentralized diagnosis, community awareness, and availability of essential antifungal eye drops. Within the GCC, treatment demand is shaped by advanced tertiary healthcare infrastructure, international patient flows, dry environmental conditions affecting ocular surface health, trauma exposure, and the need for specialist corneal services supported by microbiology and pharmacy capabilities. The European Union emphasizes regulated medicine access, cross-border clinical standards, laboratory-based diagnosis, pharmacovigilance, and antimicrobial stewardship, supporting a structured approach to fungal keratitis management even as rare or complex cases require specialist referral.

BRICS countries represent a diverse treatment environment, combining large rural populations, tropical and temperate fungal exposure patterns, expanding ophthalmology infrastructure, and significant opportunities to improve early diagnosis and affordable antifungal access. G7 countries generally benefit from advanced diagnostics, corneal transplantation capacity, specialist networks, and digital health readiness, but still face challenges related to delayed recognition, contact lens hygiene, antifungal compounding access, and clinical differentiation from other forms of infectious keratitis. NATO member countries include varied healthcare systems, many with established emergency ophthalmology pathways and military or occupational trauma considerations that reinforce the need for rapid corneal infection triage. Across these country groups, priorities converge around diagnostic accuracy, secure antifungal supply, standardized treatment protocols, and capacity building for ophthalmologists, optometrists, emergency clinicians, and microbiology teams.

Key Country Insights

The United States and Canada benefit from strong corneal subspecialty networks, diagnostic laboratories, and access to advanced imaging, with treatment often centered on rapid referral, culture-directed therapy, compounded antifungals where needed, and surgical management for severe disease. Mexico and Brazil face greater heterogeneity in access, with agricultural exposure, tropical climates in many regions, and variable availability of specialist care influencing the need for earlier recognition and stronger referral systems. In the United Kingdom, Germany, France, Italy, and Spain, fungal keratitis treatment is supported by established ophthalmology services, laboratory diagnostics, and corneal transplantation programs, while clinical vigilance remains important because the condition is less common than bacterial keratitis and can be misdiagnosed in early stages.

Russia presents a geographically diverse care environment in which urban tertiary centers may offer advanced ophthalmic management while remote areas require stronger diagnostic and referral connectivity. China and India are especially important in the global clinical landscape because large populations, agricultural exposure, contact lens adoption in urban areas, and regional climatic variation create diverse fungal keratitis presentations; India in particular has extensive published evidence linking fungal keratitis to corneal trauma and filamentous fungi. Japan, Australia, and South Korea combine advanced healthcare systems with high diagnostic capability, contact lens-related risk awareness, and specialist corneal care, while also needing continued emphasis on prompt differentiation of fungal ulcers from bacterial and viral keratitis. Across these countries, clinical success depends on fast presentation, corneal scraping before inappropriate therapy when feasible, access to effective topical antifungals, adherence support, and escalation pathways for ulcers at risk of perforation.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize antifungal access, diagnostic acceleration, and clinician workflow integration. Ensuring reliable availability of ophthalmic natamycin, amphotericin B preparations, and relevant azole formulations is fundamental, particularly in regions where delayed treatment contributes to avoidable corneal blindness. Stakeholders should support validated diagnostic pathways that combine clinical evaluation with microscopy, culture, molecular testing where appropriate, and digital imaging for treatment monitoring.

Product development and service strategies should focus on better corneal penetration, reduced dosing burden, improved tolerability, and packaging that supports adherence during intensive treatment schedules. Partnerships with hospitals, eye institutes, public health programs, and teleophthalmology networks can improve rural triage and referral. Training initiatives should target ophthalmologists, optometrists, emergency care providers, pharmacists, and community health workers on fungal keratitis risk factors, early warning signs, steroid caution, and urgent referral criteria. Leaders should also invest in real-world evidence generation, species-level surveillance, antifungal susceptibility monitoring, and AI tools validated across diverse patient populations and imaging settings.

Research Methodology

This executive summary is built on a structured secondary research approach using peer-reviewed ophthalmology literature, clinical practice guidelines, public health publications, regulatory references, disease surveillance resources, and evidence from corneal infection studies. The analysis emphasizes verified clinical facts related to fungal keratitis etiology, risk factors, diagnostic practices, treatment options, care pathways, regional access differences, and emerging technology adoption.

The methodology excludes market sizing, market estimation, market share analysis, and forecasting. Insights were synthesized through cross-comparison of epidemiological patterns, treatment standards, antifungal use cases, diagnostic availability, and healthcare infrastructure considerations across regions, country groups, and selected national markets. Particular attention was given to evidence consistency, clinical relevance, and applicability to decision-makers involved in ophthalmic drug development, diagnostics, hospital procurement, public health planning, and eye care delivery. The resulting narrative is designed to support strategic understanding while maintaining alignment with data-backed clinical and healthcare system evidence.

Conclusion

Fungal keratitis treatment remains a high-priority area in corneal infection care because delays in diagnosis and therapy can lead to scarring, perforation, keratoplasty, and irreversible vision loss. The clinical landscape is shifting toward earlier organism identification, standardized antifungal protocols, improved referral pathways, and broader use of imaging and digital decision support. Artificial intelligence, teleophthalmology, and advanced diagnostics can strengthen triage and monitoring, especially where corneal specialists are scarce, but must be implemented with rigorous validation and clinician oversight.

Regional and country-level differences underscore the need for tailored strategies. Tropical, agricultural, and resource-constrained settings require stronger access to essential antifungals and microbiology, while advanced healthcare systems must continue improving early recognition, contact lens safety, and individualized management of complex cases. For industry leaders, the most durable opportunities lie in improving treatment accessibility, diagnostic speed, adherence support, and evidence-based care integration. A coordinated approach across clinicians, laboratories, payers, policymakers, and product innovators can reduce preventable blindness and improve outcomes for patients affected by fungal keratitis.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. New Revenue Opportunities
  • 3.5. Next-Generation Business Models
  • 3.6. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Fungal Keratitis Treatment Market, by Fungal Species

  • 7.1. Introduction
  • 7.2. Filamentous Fungi
    • 7.2.1. Fusarium Species
    • 7.2.2. Aspergillus Species
    • 7.2.3. Curvularia Species
  • 7.3. Yeast-like Fungi
    • 7.3.1. Cryptococcus Species
    • 7.3.2. Candida Species

8. Fungal Keratitis Treatment Market, by Treatment Modality

  • 8.1. Introduction
  • 8.2. Surgical Interventions
  • 8.3. Systemic Antifungals
  • 8.4. Topical Antifungals

9. Fungal Keratitis Treatment Market, by Drug Class

  • 9.1. Introduction
  • 9.2. Azoles
    • 9.2.1. Imidazoles
      • 9.2.1.1. Econazole
      • 9.2.1.2. Ketoconazole
    • 9.2.2. Triazoles
      • 9.2.2.1. Fluconazole
      • 9.2.2.2. Itraconazole
      • 9.2.2.3. Voriconazole
  • 9.3. Echinocandins
    • 9.3.1. Caspofungin
    • 9.3.2. Micafungin
  • 9.4. Polyenes
    • 9.4.1. Amphotericin B
    • 9.4.2. Natamycin

10. Fungal Keratitis Treatment Market, by Route of Administration

  • 10.1. Introduction
  • 10.2. Topical
  • 10.3. Intrastromal
  • 10.4. Intracameral

11. Fungal Keratitis Treatment Market, by Age group

  • 11.1. Introduction
  • 11.2. Pediatric
  • 11.3. Adult
  • 11.4. Geriatric

12. Fungal Keratitis Treatment Market, by End User

  • 12.1. Introduction
  • 12.2. Ambulatory Surgical Centers
  • 12.3. Clinics
  • 12.4. Eye Specialty Centers
  • 12.5. Hospitals

13. Fungal Keratitis Treatment Market, by Distribution Channel

  • 13.1. Introduction
  • 13.2. Offline Retail
  • 13.3. Online Retail

14. Fungal Keratitis Treatment Market, by Region

  • 14.1. Asia-Pacific
  • 14.2. North America
  • 14.3. Latin America
  • 14.4. Europe
  • 14.5. Middle East
  • 14.6. Africa

15. Fungal Keratitis Treatment Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Fungal Keratitis Treatment Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. Competitive Landscape

  • 17.1. Market Share Analysis, 2025
  • 17.2. FPNV Positioning Matrix, 2025
  • 17.3. Market Concentration Analysis, 2025
    • 17.3.1. Concentration Ratio (CR)
    • 17.3.2. Herfindahl Hirschman Index (HHI)
  • 17.4. Recent Developments & Impact Analysis, 2025
  • 17.5. Product Portfolio Analysis, 2025
  • 17.6. Benchmarking Analysis, 2025

18. Company Profiles

  • 18.1. AbbVie Inc.
  • 18.2. Alvogen Inc.
  • 18.3. AS Lifesciences
  • 18.4. Astellas Pharma Inc.
  • 18.5. Aurolab
  • 18.6. Bausch Health Companies Inc.
  • 18.7. Cipla Ltd.
  • 18.8. F2G Ltd.
  • 18.9. Gilead Sciences Inc.
  • 18.10. Glenmark Pharmaceuticals Ltd.
  • 18.11. Grevis Pharmaceuticals Pvt. Ltd.
  • 18.12. Iskon Remedies
  • 18.13. Leadiant Biosciences Inc.
  • 18.14. Lexicare Pharma Pvt. Ltd.
  • 18.15. Merck KGaA
  • 18.16. Novartis AG
  • 18.17. Pfizer Inc.
  • 18.18. Salvus Pharma
  • 18.19. Santen Pharmaceutical Co., Ltd.
  • 18.20. Scynexis Inc.
  • 18.21. Sun Pharmaceutical Industries Ltd.
  • 18.22. Taj Pharmaceuticals Ltd.
  • 18.23. Viatris Inc.
  • 18.24. Wellona Pharma

LIST OF FIGURES

  • FIGURE 1. GLOBAL FUNGAL KERATITIS TREATMENT MARKET, YEARS CONSIDERED FOR THE STUDY
  • FIGURE 2. GLOBAL FUNGAL KERATITIS TREATMENT MARKET, RESEARCH DESIGN
  • FIGURE 3. GLOBAL FUNGAL KERATITIS TREATMENT MARKET, RESEARCH FRAMEWORK
  • FIGURE 4. GLOBAL FUNGAL KERATITIS TREATMENT MARKET, DATA TRIANGULATION
  • FIGURE 5. GLOBAL FUNGAL KERATITIS TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 6. GLOBAL FUNGAL KERATITIS TREATMENT MARKET SIZE, BY FUNGAL SPECIES, 2025 VS 2032 (%)
  • FIGURE 7. GLOBAL FUNGAL KERATITIS TREATMENT MARKET SIZE, BY FUNGAL SPECIES, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL FUNGAL KERATITIS TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2025 VS 2032 (%)
  • FIGURE 9. GLOBAL FUNGAL KERATITIS TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL FUNGAL KERATITIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2025 VS 2032 (%)
  • FIGURE 11. GLOBAL FUNGAL KERATITIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL FUNGAL KERATITIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2032 (%)
  • FIGURE 13. GLOBAL FUNGAL KERATITIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL FUNGAL KERATITIS TREATMENT MARKET SIZE, BY AGE GROUP, 2025 VS 2032 (%)
  • FIGURE 15. GLOBAL FUNGAL KERATITIS TREATMENT MARKET SIZE, BY AGE GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL FUNGAL KERATITIS TREATMENT MARKET SIZE, BY END USER, 2025 VS 2032 (%)
  • FIGURE 17. GLOBAL FUNGAL KERATITIS TREATMENT MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 18. GLOBAL FUNGAL KERATITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2032 (%)
  • FIGURE 19. GLOBAL FUNGAL KERATITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 20. GLOBAL FUNGAL KERATITIS TREATMENT MARKET SIZE, BY REGION, 2025 VS 2032 (%)
  • FIGURE 21. GLOBAL FUNGAL KERATITIS TREATMENT MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 22. GLOBAL FUNGAL KERATITIS TREATMENT MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
  • FIGURE 23. GLOBAL FUNGAL KERATITIS TREATMENT MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 24. GLOBAL FUNGAL KERATITIS TREATMENT MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
  • FIGURE 25. GLOBAL FUNGAL KERATITIS TREATMENT MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 26. GLOBAL FUNGAL KERATITIS TREATMENT MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 27. GLOBAL FUNGAL KERATITIS TREATMENT MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025

LIST OF TABLES

  • TABLE 1. GLOBAL FUNGAL KERATITIS TREATMENT MARKET SEGMENTATION & COVERAGE
  • TABLE 2. GLOBAL FUNGAL KERATITIS TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL FUNGAL KERATITIS TREATMENT MARKET SIZE, BY FUNGAL SPECIES, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL FILAMENTOUS FUNGI MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL FILAMENTOUS FUNGI MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL FILAMENTOUS FUNGI MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL FUSARIUM SPECIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL FUSARIUM SPECIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL FUSARIUM SPECIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL ASPERGILLUS SPECIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL ASPERGILLUS SPECIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL ASPERGILLUS SPECIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL CURVULARIA SPECIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL CURVULARIA SPECIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL CURVULARIA SPECIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL YEAST-LIKE FUNGI MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL YEAST-LIKE FUNGI MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL YEAST-LIKE FUNGI MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL CRYPTOCOCCUS SPECIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL CRYPTOCOCCUS SPECIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL CRYPTOCOCCUS SPECIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL CANDIDA SPECIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL CANDIDA SPECIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL CANDIDA SPECIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL FUNGAL KERATITIS TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL SURGICAL INTERVENTIONS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL SURGICAL INTERVENTIONS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL SURGICAL INTERVENTIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL SYSTEMIC ANTIFUNGALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL SYSTEMIC ANTIFUNGALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL SYSTEMIC ANTIFUNGALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL TOPICAL ANTIFUNGALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL TOPICAL ANTIFUNGALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL TOPICAL ANTIFUNGALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL FUNGAL KERATITIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL AZOLES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL AZOLES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL AZOLES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL IMIDAZOLES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL IMIDAZOLES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL IMIDAZOLES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL ECONAZOLE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL ECONAZOLE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL ECONAZOLE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL KETOCONAZOLE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL KETOCONAZOLE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL KETOCONAZOLE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL TRIAZOLES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL TRIAZOLES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL TRIAZOLES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL FLUCONAZOLE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL FLUCONAZOLE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL FLUCONAZOLE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL ITRACONAZOLE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL ITRACONAZOLE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL ITRACONAZOLE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL VORICONAZOLE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL VORICONAZOLE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL VORICONAZOLE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL ECHINOCANDINS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL ECHINOCANDINS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL ECHINOCANDINS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL CASPOFUNGIN MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL CASPOFUNGIN MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL CASPOFUNGIN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL MICAFUNGIN MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL MICAFUNGIN MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL MICAFUNGIN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL POLYENES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL POLYENES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL POLYENES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL AMPHOTERICIN B MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL AMPHOTERICIN B MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL AMPHOTERICIN B MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL NATAMYCIN MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL NATAMYCIN MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL NATAMYCIN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL FUNGAL KERATITIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL TOPICAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL TOPICAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL TOPICAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL INTRASTROMAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL INTRASTROMAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL INTRASTROMAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL INTRACAMERAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL INTRACAMERAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL INTRACAMERAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL FUNGAL KERATITIS TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL PEDIATRIC MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL PEDIATRIC MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL PEDIATRIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL ADULT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL ADULT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL ADULT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL GERIATRIC MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL GERIATRIC MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL GERIATRIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL FUNGAL KERATITIS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL AMBULATORY SURGICAL CENTERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL AMBULATORY SURGICAL CENTERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL AMBULATORY SURGICAL CENTERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL CLINICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL CLINICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL CLINICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL EYE SPECIALTY CENTERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL EYE SPECIALTY CENTERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL EYE SPECIALTY CENTERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL HOSPITALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL HOSPITALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL HOSPITALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL FUNGAL KERATITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL OFFLINE RETAIL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL OFFLINE RETAIL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL OFFLINE RETAIL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL ONLINE RETAIL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL ONLINE RETAIL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL ONLINE RETAIL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL FUNGAL KERATITIS TREATMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 119. ASIA-PACIFIC FUNGAL KERATITIS TREATMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 120. ASIA-PACIFIC FUNGAL KERATITIS TREATMENT MARKET SIZE, BY FUNGAL SPECIES, 2018-2032 (USD MILLION)
  • TABLE 121. ASIA-PACIFIC FUNGAL KERATITIS TREATMENT MARKET SIZE, BY FILAMENTOUS FUNGI, 2018-2032 (USD MILLION)
  • TABLE 122. ASIA-PACIFIC FUNGAL KERATITIS TREATMENT MARKET SIZE, BY YEAST-LIKE FUNGI, 2018-2032 (USD MILLION)
  • TABLE 123. ASIA-PACIFIC FUNGAL KERATITIS TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 124. ASIA-PACIFIC FUNGAL KERATITIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 125. ASIA-PACIFIC FUNGAL KERATITIS TREATMENT MARKET SIZE, BY AZOLES, 2018-2032 (USD MILLION)
  • TABLE 126. ASIA-PACIFIC FUNGAL KERATITIS TREATMENT MARKET SIZE, BY IMIDAZOLES, 2018-2032 (USD MILLION)
  • TABLE 127. ASIA-PACIFIC FUNGAL KERATITIS TREATMENT MARKET SIZE, BY TRIAZOLES, 2018-2032 (USD MILLION)
  • TABLE 128. ASIA-PACIFIC FUNGAL KERATITIS TREATMENT MARKET SIZE, BY ECHINOCANDINS, 2018-2032 (USD MILLION)
  • TABLE 129. ASIA-PACIFIC FUNGAL KERATITIS TREATMENT MARKET SIZE, BY POLYENES, 2018-2032 (USD MILLION)
  • TABLE 130. ASIA-PACIFIC FUNGAL KERATITIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 131. ASIA-PACIFIC FUNGAL KERATITIS TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 132. ASIA-PACIFIC FUNGAL KERATITIS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 133. ASIA-PACIFIC FUNGAL KERATITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 134. NORTH AMERICA FUNGAL KERATITIS TREATMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 135. NORTH AMERICA FUNGAL KERATITIS TREATMENT MARKET SIZE, BY FUNGAL SPECIES, 2018-2032 (USD MILLION)
  • TABLE 136. NORTH AMERICA FUNGAL KERATITIS TREATMENT MARKET SIZE, BY FILAMENTOUS FUNGI, 2018-2032 (USD MILLION)
  • TABLE 137. NORTH AMERICA FUNGAL KERATITIS TREATMENT MARKET SIZE, BY YEAST-LIKE FUNGI, 2018-2032 (USD MILLION)
  • TABLE 138. NORTH AMERICA FUNGAL KERATITIS TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 139. NORTH AMERICA FUNGAL KERATITIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 140. NORTH AMERICA FUNGAL KERATITIS TREATMENT MARKET SIZE, BY AZOLES, 2018-2032 (USD MILLION)
  • TABLE 141. NORTH AMERICA FUNGAL KERATITIS TREATMENT MARKET SIZE, BY IMIDAZOLES, 2018-2032 (USD MILLION)
  • TABLE 142. NORTH AMERICA FUNGAL KERATITIS TREATMENT MARKET SIZE, BY TRIAZOLES, 2018-2032 (USD MILLION)
  • TABLE 143. NORTH AMERICA FUNGAL KERATITIS TREATMENT MARKET SIZE, BY ECHINOCANDINS, 2018-2032 (USD MILLION)
  • TABLE 144. NORTH AMERICA FUNGAL KERATITIS TREATMENT MARKET SIZE, BY POLYENES, 2018-2032 (USD MILLION)
  • TABLE 145. NORTH AMERICA FUNGAL KERATITIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 146. NORTH AMERICA FUNGAL KERATITIS TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 147. NORTH AMERICA FUNGAL KERATITIS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 148. NORTH AMERICA FUNGAL KERATITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 149. LATIN AMERICA FUNGAL KERATITIS TREATMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 150. LATIN AMERICA FUNGAL KERATITIS TREATMENT MARKET SIZE, BY FUNGAL SPECIES, 2018-2032 (USD MILLION)
  • TABLE 151. LATIN AMERICA FUNGAL KERATITIS TREATMENT MARKET SIZE, BY FILAMENTOUS FUNGI, 2018-2032 (USD MILLION)
  • TABLE 152. LATIN AMERICA FUNGAL KERATITIS TREATMENT MARKET SIZE, BY YEAST-LIKE FUNGI, 2018-2032 (USD MILLION)
  • TABLE 153. LATIN AMERICA FUNGAL KERATITIS TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 154. LATIN AMERICA FUNGAL KERATITIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 155. LATIN AMERICA FUNGAL KERATITIS TREATMENT MARKET SIZE, BY AZOLES, 2018-2032 (USD MILLION)
  • TABLE 156. LATIN AMERICA FUNGAL KERATITIS TREATMENT MARKET SIZE, BY IMIDAZOLES, 2018-2032 (USD MILLION)
  • TABLE 157. LATIN AMERICA FUNGAL KERATITIS TREATMENT MARKET SIZE, BY TRIAZOLES, 2018-2032 (USD MILLION)
  • TABLE 158. LATIN AMERICA FUNGAL KERATITIS TREATMENT MARKET SIZE, BY ECHINOCANDINS, 2018-2032 (USD MILLION)
  • TABLE 159. LATIN AMERICA FUNGAL KERATITIS TREATMENT MARKET SIZE, BY POLYENES, 2018-2032 (USD MILLION)
  • TABLE 160. LATIN AMERICA FUNGAL KERATITIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 161. LATIN AMERICA FUNGAL KERATITIS TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 162. LATIN AMERICA FUNGAL KERATITIS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 163. LATIN AMERICA FUNGAL KERATITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 164. EUROPE FUNGAL KERATITIS TREATMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 165. EUROPE FUNGAL KERATITIS TREATMENT MARKET SIZE, BY FUNGAL SPECIES, 2018-2032 (USD MILLION)
  • TABLE 166. EUROPE FUNGAL KERATITIS TREATMENT MARKET SIZE, BY FILAMENTOUS FUNGI, 2018-2032 (USD MILLION)
  • TABLE 167. EUROPE FUNGAL KERATITIS TREATMENT MARKET SIZE, BY YEAST-LIKE FUNGI, 2018-2032 (USD MILLION)
  • TABLE 168. EUROPE FUNGAL KERATITIS TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 169. EUROPE FUNGAL KERATITIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 170. EUROPE FUNGAL KERATITIS TREATMENT MARKET SIZE, BY AZOLES, 2018-2032 (USD MILLION)
  • TABLE 171. EUROPE FUNGAL KERATITIS TREATMENT MARKET SIZE, BY IMIDAZOLES, 2018-2032 (USD MILLION)
  • TABLE 172. EUROPE FUNGAL KERATITIS TREATMENT MARKET SIZE, BY TRIAZOLES, 2018-2032 (USD MILLION)
  • TABLE 173. EUROPE FUNGAL KERATITIS TREATMENT MARKET SIZE, BY ECHINOCANDINS, 2018-2032 (USD MILLION)
  • TABLE 174. EUROPE FUNGAL KERATITIS TREATMENT MARKET SIZE, BY POLYENES, 2018-2032 (USD MILLION)
  • TABLE 175. EUROPE FUNGAL KERATITIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 176. EUROPE FUNGAL KERATITIS TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 177. EUROPE FUNGAL KERATITIS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 178. EUROPE FUNGAL KERATITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 179. MIDDLE EAST FUNGAL KERATITIS TREATMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 180. MIDDLE EAST FUNGAL KERATITIS TREATMENT MARKET SIZE, BY FUNGAL SPECIES, 2018-2032 (USD MILLION)
  • TABLE 181. MIDDLE EAST FUNGAL KERATITIS TREATMENT MARKET SIZE, BY FILAMENTOUS FUNGI, 2018-2032 (USD MILLION)
  • TABLE 182. MIDDLE EAST FUNGAL KERATITIS TREATMENT MARKET SIZE, BY YEAST-LIKE FUNGI, 2018-2032 (USD MILLION)
  • TABLE 183. MIDDLE EAST FUNGAL KERATITIS TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 184. MIDDLE EAST FUNGAL KERATITIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 185. MIDDLE EAST FUNGAL KERATITIS TREATMENT MARKET SIZE, BY AZOLES, 2018-2032 (USD MILLION)
  • TABLE 186. MIDDLE EAST FUNGAL KERATITIS TREATMENT MARKET SIZE, BY IMIDAZOLES, 2018-2032 (USD MILLION)
  • TABLE 187. MIDDLE EAST FUNGAL KERATITIS TREATMENT MARKET SIZE, BY TRIAZOLES, 2018-2032 (USD MILLION)
  • TABLE 188. MIDDLE EAST FUNGAL KERATITIS TREATMENT MARKET SIZE, BY ECHINOCANDINS, 2018-2032 (USD MILLION)
  • TABLE 189. MIDDLE EAST FUNGAL KERATITIS TREATMENT MARKET SIZE, BY POLYENES, 2018-2032 (USD MILLION)
  • TABLE 190. MIDDLE EAST FUNGAL KERATITIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 191. MIDDLE EAST FUNGAL KERATITIS TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 192. MIDDLE EAST FUNGAL KERATITIS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 193. MIDDLE EAST FUNGAL KERATITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 194. AFRICA FUNGAL KERATITIS TREATMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 195. AFRICA FUNGAL KERATITIS TREATMENT MARKET SIZE, BY FUNGAL SPECIES, 2018-2032 (USD MILLION)
  • TABLE 196. AFRICA FUNGAL KERATITIS TREATMENT MARKET SIZE, BY FILAMENTOUS FUNGI, 2018-2032 (USD MILLION)
  • TABLE 197. AFRICA FUNGAL KERATITIS TREATMENT MARKET SIZE, BY YEAST-LIKE FUNGI, 2018-2032 (USD MILLION)
  • TABLE 198. AFRICA FUNGAL KERATITIS TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 199. AFRICA FUNGAL KERATITIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 200. AFRICA FUNGAL KERATITIS TREATMENT MARKET SIZE, BY AZOLES, 2018-2032 (USD MILLION)
  • TABLE 201. AFRICA FUNGAL KERATITIS TREATMENT MARKET SIZE, BY IMIDAZOLES, 2018-2032 (USD MILLION)
  • TABLE 202. AFRICA FUNGAL KERATITIS TREATMENT MARKET SIZE, BY TRIAZOLES, 2018-2032 (USD MILLION)
  • TABLE 203. AFRICA FUNGAL KERATITIS TREATMENT MARKET SIZE, BY ECHINOCANDINS, 2018-2032 (USD MILLION)
  • TABLE 204. AFRICA FUNGAL KERATITIS TREATMENT MARKET SIZE, BY POLYENES, 2018-2032 (USD MILLION)
  • TABLE 205. AFRICA FUNGAL KERATITIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 206. AFRICA FUNGAL KERATITIS TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 207. AFRICA FUNGAL KERATITIS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 208. AFRICA FUNGAL KERATITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 209. GLOBAL FUNGAL KERATITIS TREATMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 210. ASEAN FUNGAL KERATITIS TREATMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 211. ASEAN FUNGAL KERATITIS TREATMENT MARKET SIZE, BY FUNGAL SPECIES, 2018-2032 (USD MILLION)
  • TABLE 212. ASEAN FUNGAL KERATITIS TREATMENT MARKET SIZE, BY FILAMENTOUS FUNGI, 2018-2032 (USD MILLION)
  • TABLE 213. ASEAN FUNGAL KERATITIS TREATMENT MARKET SIZE, BY YEAST-LIKE FUNGI, 2018-2032 (USD MILLION)
  • TABLE 214. ASEAN FUNGAL KERATITIS TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 215. ASEAN FUNGAL KERATITIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 216. ASEAN FUNGAL KERATITIS TREATMENT MARKET SIZE, BY AZOLES, 2018-2032 (USD MILLION)
  • TABLE 217. ASEAN FUNGAL KERATITIS TREATMENT MARKET SIZE, BY IMIDAZOLES, 2018-2032 (USD MILLION)
  • TABLE 218. ASEAN FUNGAL KERATITIS TREATMENT MARKET SIZE, BY TRIAZOLES, 2018-2032 (USD MILLION)
  • TABLE 219. ASEAN FUNGAL KERATITIS TREATMENT MARKET SIZE, BY ECHINOCANDINS, 2018-2032 (USD MILLION)
  • TABLE 220. ASEAN FUNGAL KERATITIS TREATMENT MARKET SIZE, BY POLYENES, 2018-2032 (USD MILLION)
  • TABLE 221. ASEAN FUNGAL KERATITIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 222. ASEAN FUNGAL KERATITIS TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 223. ASEAN FUNGAL KERATITIS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 224. ASEAN FUNGAL KERATITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 225. GCC FUNGAL KERATITIS TREATMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 226. GCC FUNGAL KERATITIS TREATMENT MARKET SIZE, BY FUNGAL SPECIES, 2018-2032 (USD MILLION)
  • TABLE 227. GCC FUNGAL KERATITIS TREATMENT MARKET SIZE, BY FILAMENTOUS FUNGI, 2018-2032 (USD MILLION)
  • TABLE 228. GCC FUNGAL KERATITIS TREATMENT MARKET SIZE, BY YEAST-LIKE FUNGI, 2018-2032 (USD MILLION)
  • TABLE 229. GCC FUNGAL KERATITIS TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 230. GCC FUNGAL KERATITIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 231. GCC FUNGAL KERATITIS TREATMENT MARKET SIZE, BY AZOLES, 2018-2032 (USD MILLION)
  • TABLE 232. GCC FUNGAL KERATITIS TREATMENT MARKET SIZE, BY IMIDAZOLES, 2018-2032 (USD MILLION)
  • TABLE 233. GCC FUNGAL KERATITIS TREATMENT MARKET SIZE, BY TRIAZOLES, 2018-2032 (USD MILLION)
  • TABLE 234. GCC FUNGAL KERATITIS TREATMENT MARKET SIZE, BY ECHINOCANDINS, 2018-2032 (USD MILLION)
  • TABLE 235. GCC FUNGAL KERATITIS TREATMENT MARKET SIZE, BY POLYENES, 2018-2032 (USD MILLION)
  • TABLE 236. GCC FUNGAL KERATITIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 237. GCC FUNGAL KERATITIS TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 238. GCC FUNGAL KERATITIS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 239. GCC FUNGAL KERATITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 240. EUROPEAN UNION FUNGAL KERATITIS TREATMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 241. EUROPEAN UNION FUNGAL KERATITIS TREATMENT MARKET SIZE, BY FUNGAL SPECIES, 2018-2032 (USD MILLION)
  • TABLE 242. EUROPEAN UNION FUNGAL KERATITIS TREATMENT MARKET SIZE, BY FILAMENTOUS FUNGI, 2018-2032 (USD MILLION)
  • TABLE 243. EUROPEAN UNION FUNGAL KERATITIS TREATMENT MARKET SIZE, BY YEAST-LIKE FUNGI, 2018-2032 (USD MILLION)
  • TABLE 244. EUROPEAN UNION FUNGAL KERATITIS TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 245. EUROPEAN UNION FUNGAL KERATITIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 246. EUROPEAN UNION FUNGAL KERATITIS TREATMENT MARKET SIZE, BY AZOLES, 2018-2032 (USD MILLION)
  • TABLE 247. EUROPEAN UNION FUNGAL KERATITIS TREATMENT MARKET SIZE, BY IMIDAZOLES, 2018-2032 (USD MILLION)
  • TABLE 248. EUROPEAN UNION FUNGAL KERATITIS TREATMENT MARKET SIZE, BY TRIAZOLES, 2018-2032 (USD MILLION)
  • TABLE 249. EUROPEAN UNION FUNGAL KERATITIS TREATMENT MARKET SIZE, BY ECHINOCANDINS, 2018-2032 (USD MILLION)
  • TABLE 250. EUROPEAN UNION FUNGAL KERATITIS TREATMENT MARKET SIZE, BY POLYENES, 2018-2032 (USD MILLION)
  • TABLE 251. EUROPEAN UNION FUNGAL KERATITIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 252. EUROPEAN UNION FUNGAL KERATITIS TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 253. EUROPEAN UNION FUNGAL KERATITIS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 254. EUROPEAN UNION FUNGAL KERATITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 255. BRICS FUNGAL KERATITIS TREATMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 256. BRICS FUNGAL KERATITIS TREATMENT MARKET SIZE, BY FUNGAL SPECIES, 2018-2032 (USD MILLION)
  • TABLE 257. BRICS FUNGAL KERATITIS TREATMENT MARKET SIZE, BY FILAMENTOUS FUNGI, 2018-2032 (USD MILLION)
  • TABLE 258. BRICS FUNGAL KERATITIS TREATMENT MARKET SIZE, BY YEAST-LIKE FUNGI, 2018-2032 (USD MILLION)
  • TABLE 259. BRICS FUNGAL KERATITIS TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 260. BRICS FUNGAL KERATITIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 261. BRICS FUNGAL KERATITIS TREATMENT MARKET SIZE, BY AZOLES, 2018-2032 (USD MILLION)
  • TABLE 262. BRICS FUNGAL KERATITIS TREATMENT MARKET SIZE, BY IMIDAZOLES, 2018-2032 (USD MILLION)
  • TABLE 263. BRICS FUNGAL KERATITIS TREATMENT MARKET SIZE, BY TRIAZOLES, 2018-2032 (USD MILLION)
  • TABLE 264. BRICS FUNGAL KERATITIS TREATMENT MARKET SIZE, BY ECHINOCANDINS, 2018-2032 (USD MILLION)
  • TABLE 265. BRICS FUNGAL KERATITIS TREATMENT MARKET SIZE, BY POLYENES, 2018-2032 (USD MILLION)
  • TABLE 266. BRICS FUNGAL KERATITIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 267. BRICS FUNGAL KERATITIS TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 268. BRICS FUNGAL KERATITIS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 269. BRICS FUNGAL KERATITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 270. G7 FUNGAL KERATITIS TREATMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 271. G7 FUNGAL KERATITIS TREATMENT MARKET SIZE, BY FUNGAL SPECIES, 2018-2032 (USD MILLION)
  • TABLE 272. G7 FUNGAL KERATITIS TREATMENT MARKET SIZE, BY FILAMENTOUS FUNGI, 2018-2032 (USD MILLION)
  • TABLE 273. G7 FUNGAL KERATITIS TREATMENT MARKET SIZE, BY YEAST-LIKE FUNGI, 2018-2032 (USD MILLION)
  • TABLE 274. G7 FUNGAL KERATITIS TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 275. G7 FUNGAL KERATITIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 276. G7 FUNGAL KERATITIS TREATMENT MARKET SIZE, BY AZOLES, 2018-2032 (USD MILLION)
  • TABLE 277. G7 FUNGAL KERATITIS TREATMENT MARKET SIZE, BY IMIDAZOLES, 2018-2032 (USD MILLION)
  • TABLE 278. G7 FUNGAL KERATITIS TREATMENT MARKET SIZE, BY TRIAZOLES, 2018-2032 (USD MILLION)
  • TABLE 279. G7 FUNGAL KERATITIS TREATMENT MARKET SIZE, BY ECHINOCANDINS, 2018-2032 (USD MILLION)
  • TABLE 280. G7 FUNGAL KERATITIS TREATMENT MARKET SIZE, BY POLYENES, 2018-2032 (USD MILLION)
  • TABLE 281. G7 FUNGAL KERATITIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 282. G7 FUNGAL KERATITIS TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 283. G7 FUNGAL KERATITIS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 284. G7 FUNGAL KERATITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 285. NATO FUNGAL KERATITIS TREATMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 286. NATO FUNGAL KERATITIS TREATMENT MARKET SIZE, BY FUNGAL SPECIES, 2018-2032 (USD MILLION)
  • TABLE 287. NATO FUNGAL KERATITIS TREATMENT MARKET SIZE, BY FILAMENTOUS FUNGI, 2018-2032 (USD MILLION)
  • TABLE 288. NATO FUNGAL KERATITIS TREATMENT MARKET SIZE, BY YEAST-LIKE FUNGI, 2018-2032 (USD MILLION)
  • TABLE 289. NATO FUNGAL KERATITIS TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 290. NATO FUNGAL KERATITIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 291. NATO FUNGAL KERATITIS TREATMENT MARKET SIZE, BY AZOLES, 2018-2032 (USD MILLION)
  • TABLE 292. NATO FUNGAL KERATITIS TREATMENT MARKET SIZE, BY IMIDAZOLES, 2018-2032 (USD MILLION)
  • TABLE 293. NATO FUNGAL KERATITIS TREATMENT MARKET SIZE, BY TRIAZOLES, 2018-2032 (USD MILLION)
  • TABLE 294. NATO FUNGAL KERATITIS TREATMENT MARKET SIZE, BY ECHINOCANDINS, 2018-2032 (USD MILLION)
  • TABLE 295. NATO FUNGAL KERATITIS TREATMENT MARKET SIZE, BY POLYENES, 2018-2032 (USD MILLION)
  • TABLE 296. NATO FUNGAL KERATITIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 297. NATO FUNGAL KERATITIS TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 298. NATO FUNGAL KERATITIS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 299. NATO FUNGAL KERATITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 300. GLOBAL FUNGAL KERATITIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 301. UNITED STATES FUNGAL KERATITIS TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 302. UNITED STATES FUNGAL KERATITIS TREATMENT MARKET SIZE, BY FUNGAL SPECIES, 2018-2032 (USD MILLION)
  • TABLE 303. UNITED STATES FUNGAL KERATITIS TREATMENT MARKET SIZE, BY FILAMENTOUS FUNGI, 2018-2032 (USD MILLION)
  • TABLE 304. UNITED STATES FUNGAL KERATITIS TREATMENT MARKET SIZE, BY YEAST-LIKE FUNGI, 2018-2032 (USD MILLION)
  • TABLE 305. UNITED STATES FUNGAL KERATITIS TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 306. UNITED STATES FUNGAL KERATITIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 307. UNITED STATES FUNGAL KERATITIS TREATMENT MARKET SIZE, BY AZOLES, 2018-2032 (USD MILLION)
  • TABLE 308. UNITED STATES FUNGAL KERATITIS TREATMENT MARKET SIZE, BY IMIDAZOLES, 2018-2032 (USD MILLION)
  • TABLE 309. UNITED STATES FUNGAL KERATITIS TREATMENT MARKET SIZE, BY TRIAZOLES, 2018-2032 (USD MILLION)
  • TABLE 310. UNITED STATES FUNGAL KERATITIS TREATMENT MARKET SIZE, BY ECHINOCANDINS, 2018-2032 (USD MILLION)
  • TABLE 311. UNITED STATES FUNGAL KERATITIS TREATMENT MARKET SIZE, BY POLYENES, 2018-2032 (USD MILLION)
  • TABLE 312. UNITED STATES FUNGAL KERATITIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 313. UNITED STATES FUNGAL KERATITIS TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 314. UNITED STATES FUNGAL KERATITIS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 315. UNITED STATES FUNGAL KERATITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 316. CANADA FUNGAL KERATITIS TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 317. CANADA FUNGAL KERATITIS TREATMENT MARKET SIZE, BY FUNGAL SPECIES, 2018-2032 (USD MILLION)
  • TABLE 318. CANADA FUNGAL KERATITIS TREATMENT MARKET SIZE, BY FILAMENTOUS FUNGI, 2018-2032 (USD MILLION)
  • TABLE 319. CANADA FUNGAL KERATITIS TREATMENT MARKET SIZE, BY YEAST-LIKE FUNGI, 2018-2032 (USD MILLION)
  • TABLE 320. CANADA FUNGAL KERATITIS TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 321. CANADA FUNGAL KERATITIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 322. CANADA FUNGAL KERATITIS TREATMENT MARKET SIZE, BY AZOLES, 2018-2032 (USD MILLION)
  • TABLE 323. CANADA FUNGAL KERATITIS TREATMENT MARKET SIZE, BY IMIDAZOLES, 2018-2032 (USD MILLION)
  • TABLE 324. CANADA FUNGAL KERATITIS TREATMENT MARKET SIZE, BY TRIAZOLES, 2018-2032 (USD MILLION)
  • TABLE 325. CANADA FUNGAL KERATITIS TREATMENT MARKET SIZE, BY ECHINOCANDINS, 2018-2032 (USD MILLION)
  • TABLE 326. CANADA FUNGAL KERATITIS TREATMENT MARKET SIZE, BY POLYENES, 2018-2032 (USD MILLION)
  • TABLE 327. CANADA FUNGAL KERATITIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 328. CANADA FUNGAL KERATITIS TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 329. CANADA FUNGAL KERATITIS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 330. CANADA FUNGAL KERATITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 331. MEXICO FUNGAL KERATITIS TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 332. MEXICO FUNGAL KERATITIS TREATMENT MARKET SIZE, BY FUNGAL SPECIES, 2018-2032 (USD MILLION)
  • TABLE 333. MEXICO FUNGAL KERATITIS TREATMENT MARKET SIZE, BY FILAMENTOUS FUNGI, 2018-2032 (USD MILLION)
  • TABLE 334. MEXICO FUNGAL KERATITIS TREATMENT MARKET SIZE, BY YEAST-LIKE FUNGI, 2018-2032 (USD MILLION)
  • TABLE 335. MEXICO FUNGAL KERATITIS TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 336. MEXICO FUNGAL KERATITIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 337. MEXICO FUNGAL KERATITIS TREATMENT MARKET SIZE, BY AZOLES, 2018-2032 (USD MILLION)
  • TABLE 338. MEXICO FUNGAL KERATITIS TREATMENT MARKET SIZE, BY IMIDAZOLES, 2018-2032 (USD MILLION)
  • TABLE 339. MEXICO FUNGAL KERATITIS TREATMENT MARKET SIZE, BY TRIAZOLES, 2018-2032 (USD MILLION)
  • TABLE 340. MEXICO FUNGAL KERATITIS TREATMENT MARKET SIZE, BY ECHINOCANDINS, 2018-2032 (USD MILLION)
  • TABLE 341. MEXICO FUNGAL KERATITIS TREATMENT MARKET SIZE, BY POLYENES, 2018-2032 (USD MILLION)
  • TABLE 342. MEXICO FUNGAL KERATITIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 343. MEXICO FUNGAL KERATITIS TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 344. MEXICO FUNGAL KERATITIS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 345. MEXICO FUNGAL KERATITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 346. BRAZIL FUNGAL KERATITIS TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 347. BRAZIL FUNGAL KERATITIS TREATMENT MARKET SIZE, BY FUNGAL SPECIES, 2018-2032 (USD MILLION)
  • TABLE 348. BRAZIL FUNGAL KERATITIS TREATMENT MARKET SIZE, BY FILAMENTOUS FUNGI, 2018-2032 (USD MILLION)

TABLE 3